In the two obese DM1 patients with concurrent diabetes (136), after 10 days of pioglitazone treatment, not only was blood glucose improved, but levels of inflammatory markers in serum, including interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP), also decreased significantly, while the anti-inflammatory adiponectin levels notably increased. This evidence concerns the gene IL6 and diabetes mellitus.